scarlet1967 wrote: Any stock is promotable although sore subject just look at CYDY their stock was trade between 0.30and 0.70 cents most of 2019 so the market didn't ascribe decent valuation to the company due to "long history of the company" yet in June 2020 the stock reached the all time high of $10 US vs 0.30 cents in October 2019 some 8 months later more than 30 fold appreciation!
Why, because they didn't have much to work with initially until their wonder drug was considered for MDR, NASH and covid19 and they manage to convince the market by decent promotional efforts ,to date they haven't proove anything which support the validity of the drug actually can address any of those conditions.
THTX has been growing sales during lockdowns, will in March start the PDC trial with a mega market and also projected to start phase 3 in few months so how is that nobody ascribe a decent valuation to this company? Short answer, wrong marketing strategies.
jfm1330 wrote: A lot of venting on this board, rehashing the same complaints, also a lot of people here that think they would do a much better job than the bord and management. For many Tanguay was the problem. Levesque his on its way to become the new problem for the same people. Remember, Tanguay was basically a finance guy. He made all the previous financings in the history of the company, and after 26 years of him doing that, the company was only at 77 M shares outstanding through all the highs and lows. So, clearly, Tanguay was careful and not strong on dilution. Many here were happy to see him leave, so sometimes you need be careful what you wish for. The same Tanguay bought back the rights to Egrifta, made the Trogarzo deal, the Katana deal, and supplied the drug for free to Grinspoon that led the company into NASH. So basically, all the assets that Thera has right now were acquired under Tanguay, the finance guy. A few months after he left, you got this huge dilution. Do you see a link?...
I am not pretending that Tanguay was perfect. He was not able to get good sales results, either for Egrifta or Trogarzo. There are reasons for that, not all his fault. But still, he was great on the finance side and on the deal making side. He was also blamed here as being unable to promote the stock. We see now that probably it was the stock that was unpromotable because of the long history of the company.